Literature DB >> 16622181

Cyclooxygenase-2 inhibition normalizes arterial blood pressure in CYP1A1-REN2 transgenic rats with inducible ANG II-dependent malignant hypertension.

Allison L Opay1, Cynthia R Mouton, John J Mullins, Kenneth D Mitchell.   

Abstract

The present study was performed to determine the effects of cyclooxygenase (COX)-1 and COX-2 inhibition on blood pressure and renal hemodynamics in transgenic rats with inducible malignant hypertension [strain name: TGR(Cyp1a1Ren2)]. Male Cyp1a1-Ren2 rats (n = 7) were fed a normal diet containing the aryl hydrocarbon, indole-3-carbinol (I3C; 0.3%), for 6-9 days to induce malignant hypertension. Mean arterial pressure (MAP) and renal hemodynamics were measured in pentobarbital sodium-anesthetized Cyp1a1-Ren2 rats during control conditions, following administration of the COX-2 inhibitor nimesulide (3 mg/kg iv), and following administration of the nonspecific COX inhibitor meclofenamate (5 mg/kg iv). Rats induced with I3C had higher MAP than noninduced rats (n = 7; 188 +/- 6 vs. 136 +/- 4 mmHg, P < 0.01). There was no difference in renal plasma flow (RPF) or glomerular filtration rate (GFR) between induced and noninduced rats. Nimesulide elicited a larger decrease in MAP in hypertensive rats (188 +/- 6 to 140 +/- 8 mmHg, P < 0.01) than in normotensive rats (136 +/- 4 to 113 +/- 8 mmHg, P < 0.01). Additionally, nimesulide decreased GFR (0.9 +/- 0.13 to 0.44 +/- 0.05 ml.min(-1).g(-1), P < 0.05) and RPF (2.79 +/- 0.27 to 1.35 +/- 0.14 ml.min(-1).g(-1), P < 0.05) in hypertensive rats but did not alter GFR or RPF in normotensive rats. Meclofenamate further decreased MAP in hypertensive rats (to 115 +/- 10 mmHg, P < 0.05) but did not decrease MAP in normotensive rats. Meclofenamate did not alter GFR or RPF in either group. These findings demonstrate that COX-1- and COX-2-derived prostanoids contribute importantly to the development of malignant hypertension in Cyp1a1-Ren2 transgenic rats. The data also indicate that COX-2-derived vasodilatory metabolites play an important role in the maintenance of RPF and GFR following induction of malignant hypertension in Cyp1a1-Ren2 transgenic rats.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16622181     DOI: 10.1152/ajprenal.00032.2006

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  10 in total

1.  Enhanced urinary angiotensinogen excretion in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.

Authors:  Carlo J Milani; Hiroyuki Kobori; John J Mullins; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2010-11       Impact factor: 2.378

2.  Chronic direct renin inhibition with aliskiren prevents the development of hypertension in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent hypertension.

Authors:  Lily Huang; Catherine G Howard; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2012-10       Impact factor: 2.378

3.  Renal medullary cyclooxygenase-2 and (pro)renin receptor expression during angiotensin II-dependent hypertension.

Authors:  Alexis A Gonzalez; Torrance Green; Christina Luffman; Camille R T Bourgeois; L Gabriel Navar; Minolfa C Prieto
Journal:  Am J Physiol Renal Physiol       Date:  2014-08-20

4.  Transient induction of ANG II-dependent malignant hypertension causes sustained elevation of blood pressure and augmentation of the pressor response to ANG II in CYP1A1-REN2 transgenic rats.

Authors:  Catherine G Howard; John J Mullins; Kenneth D Mitchell
Journal:  Am J Med Sci       Date:  2010-06       Impact factor: 2.378

Review 5.  The complex interplay between cyclooxygenase-2 and angiotensin II in regulating kidney function.

Authors:  Torrance Green; Alexis A Gonzalez; Kenneth D Mitchell; L Gabriel Navar
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-01       Impact factor: 2.894

6.  Imatinib ameliorates renal morphological changes in Cyp1a1-Ren2 transgenic rats with inducible ANG II-dependent malignant hypertension.

Authors:  Miguel L Graciano; Kenneth D Mitchell
Journal:  Am J Physiol Renal Physiol       Date:  2011-10-05

7.  Renal functional responses to selective intrarenal renin inhibition in Cyp1a1-Ren2 transgenic rats with ANG II-dependent malignant hypertension.

Authors:  Catherine G Howard; Kenneth D Mitchell
Journal:  Am J Physiol Renal Physiol       Date:  2011-10-12

8.  Augmented cyclooxygenase-2 effects on renal function during varying states of angiotensin II.

Authors:  Torrance Green; Jorge Rodriguez; L Gabriel Navar
Journal:  Am J Physiol Renal Physiol       Date:  2010-07-28

9.  Angiotensin-converting enzyme is a modifier of hypertensive end organ damage.

Authors:  Xiaojun Liu; Christopher O C Bellamy; Matthew A Bailey; Linda J Mullins; Donald R Dunbar; Christopher J Kenyon; Gillian Brooker; Surasak Kantachuvesiri; Klio Maratou; Ali Ashek; Allan F Clark; Stewart Fleming; John J Mullins
Journal:  J Biol Chem       Date:  2009-03-23       Impact factor: 5.157

10.  The renin-angiotensin system as a primary cause of polyarteritis nodosa in rats.

Authors:  Barbara S Peters; Beate Kuttler; Andreas Beineke; Gerd Lorenz; Andrea Thiele; Oliver Nicolai; Rainer Rettig; John J Mullins; Jörg Peters
Journal:  J Cell Mol Med       Date:  2009-05-11       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.